Actinium Pharmaceuticals Inc (ATNM)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.03-1.90%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ATNM
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | 0.1 | — | 0.1 | 1.0 | 1.1 | — | — | — | — | — | — | — | — | — | 0.0 |
| Total Revenues | — | 0.1 | — | 0.1 | 1.0 | 1.1 | — | — | — | — | — | — | — | — | — | 0.0 |
| Cost of Revenues | — | — | — | — | — | 0.9 | — | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 18.1 | 21.1 | 30.0 | 38.7 | 23.1 | 18.0 | 16.1 | 16.6 | 17.1 | 17.7 | 17.8 | 13.5 | 12.3 | 3.1 | 3.4 | — |
| Operating Income | 9.6 | (36.2) | (42.1) | (51.9) | (34.1) | (25.0) | (22.4) | (22.1) | (23.8) | (26.9) | (26.8) | (24.8) | (22.5) | (6.6) | (7.9) | (3.3) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | (0.2) |
| Interest & Investment Income | 1.8 | 2.4 | 3.9 | 3.1 | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 1.8 | 2.4 | 3.9 | 3.1 | 1.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 2.5 | 3.8 | (2.2) | (4.2) | (0.4) | 0.2 |
| Income Tax Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Net Income | ||||||||||||||||
| Net Income | 11.3 | (33.9) | (38.2) | (48.8) | (33.0) | (24.8) | (22.2) | (21.9) | (23.7) | (26.6) | (24.3) | (21.0) | (24.7) | (10.8) | (8.4) | (3.4) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.36 | (1.09) | (1.27) | (1.83) | (1.37) | (1.20) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 0.36 | (1.09) | (1.27) | (1.83) | (1.37) | (1.20) | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 31.4 | 31.2 | 30.1 | 26.6 | 24.1 | 20.6 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 31.4 | 31.2 | 30.1 | 26.6 | 24.1 | 20.6 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (36.1) | (41.9) | (51.7) | (33.4) | (24.4) | (21.9) | (21.7) | — | — | (26.8) | (24.8) | (22.4) | (6.6) | (7.9) | — |
| EBIT | 9.6 | (36.2) | (42.1) | (51.9) | (34.1) | (25.0) | (22.4) | (22.1) | (23.8) | (26.9) | (26.8) | (24.8) | (22.5) | (6.6) | (7.9) | (3.3) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.